News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Center for Business Intelligence Announces The Biotech-Pharma Oncology Partnerships Executive Conference, February 23-24, 2004



10/19/2005 5:09:38 PM

WOBURN, Mass., Jan. 8 /PRNewswire/ -- Attend CBI's Biotech-Pharma Oncology Partnerships Executive conference, February 23-24, 2004 and hear best practices and deal making presentations from the C-level and Senior Executives from biotechnology and pharmaceutical companies.

The fight for cancer has paved the way for a new era of partnerships between the pharmaceutical and biotechnology industries. The sector is moving toward an alliance network of specialty companies. A company does not have to do everything, does not have to be a mini-pharmaceutical company, to be profitable and successful. However it does have to focus on an area that is essential for bringing products to market.

By refocusing on what they do best, biotechnology and pharmaceutical companies can build networks of alliances through which each player contributes to the end product and shares in the revenues. They can generate profit-making enterprises to support other activities such as their own oncology drug development. Setting up a company that will not report earning for 10 to 15 years was a business model for the 20th century, not the 21st century.

This conference examines the emerging trends and predominant strategies for partnerships adopted by the biotechnology and pharmaceutical companies, in their focused efforts for developing oncology products.

The conference features a Biotech-Pharmaceutical Oncology Partnership Debate, facilitated by Lloyd Segal, President and CEO, Caprion Pharmaceuticals, Inc. and Steven Strand, Director, Oncology New Business, AstraZeneca. Biotechnology Panelists include: Alan Lewis, President, Signal Research Division, Celgene Corp David Ferrick, CEO, Sagres Discovery, Deanna Petersen, Vice President, Business Development, Antigenics. Pharmaceuticals Panelists include: Mark Wiggins, Vice President, Marketing and Business Development, IDEC Pharmaceuticals Corporation, George S. Golumbeski, PhD, Vice President Business Development, Licensing & Strategy, Novartis-Oncology, Stephane Andre, Ph.D, Vice President, Europe-Middle East-Africa, Worldwide Regulatory Affairs, Wyeth Pharmaceuticals.

For more information or to register, please call 800-817-8601, by fax at 781-939-2490; visit us at http://www.cbinet.com/ or email cbireg@cbinet.com

If you are interested in reaching this valuable audience check out our Sponsorship and Exhibit Packages or call Stuart Steller at 781-939-2411 or email him at s.steller@cbinet.com

Press Contact: Kim Hunter The Center for Business Intelligence 500 West Cummings Park Suite 5100 Woburn, MA 01801 PH: 800-817-8601 FX: 781-939-2495 cbireg@cbinet.com http://www.cbinet.com

CBI

CONTACT: Kim Hunter of The Center for Business Intelligence,+1-800-817-8601, cbireg@cbinet.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES